Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jaime E C Hallak

Showing results (121-130 of 129) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 129 results.
Neuropharmacology|March 6, 2026
Cannabidiol reduces the latency for the behavioral effect of escitalopram in chronically stressed male mice: involvement of NAPE-PLD expressed in parvalbumin-positive interneurons and the prefrontal cortexFranciele F Scarante, Vinícius D Lopes, Eduardo J Fusse, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|November 3, 2023
Cannabidiol as an Adjunctive Treatment for Acute Bipolar Depression: A Pilot Study: Le cannabidiol comme traitement d'appoint de la dépression bipolaire aiguë : une étude piloteJairo Vinícius Pinto, José Alexandre S Crippa, Keila Maria Ceresér, et al.
Scientific Reports|April 20, 2022
Potential cannabidiol (CBD) repurposing as antibacterial and promising therapy of CBD plus polymyxin B (PB) against PB-resistant gram-negative bacilliNathália Abichabki, Luísa V Zacharias, Natália C Moreira, et al.
Psychological Medicine|June 16, 2018
Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trialFernanda Palhano-Fontes, Dayanna Barreto, Heloisa Onias, et al.
JAMA Network Open|August 13, 2021
Efficacy and Safety of Cannabidiol Plus Standard Care vs Standard Care Alone for the Treatment of Emotional Exhaustion and Burnout Among Frontline Health Care Workers During the COVID-19 Pandemic: A Randomized Clinical TrialJosé Alexandre S Crippa, Antonio W Zuardi, Francisco S Guimarães, et al.
Frontiers in Pharmacology|October 20, 2022
Maintained anxiolytic effects of cannabidiol after treatment discontinuation in healthcare workers during the COVID-19 pandemicJosé Diogo S Souza, Antonio W Zuardi, Francisco S Guimarães, et al.
Cannabis and Cannabinoid Research|October 7, 2021
Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical TrialJosé Alexandre S Crippa, Julia Cozar Pacheco, Antonio W Zuardi, et al.
The American Journal of Psychiatry|December 7, 2016
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and TerminologyOliver D Howes, Rob McCutcheon, Ofer Agid, et al.
The American Journal of Psychiatry|October 8, 2025
Relapse in Schizophrenia: A Systematic Review of Criteria for Clinical Studies and International Consensus Guidelines to Improve ThemOliver D Howes, Bernard R Bukala, Eric Y H Chen, et al.
Pageof 13

Showing results (121-130 of 129) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 129 results.
Neuropharmacology|March 6, 2026
Cannabidiol reduces the latency for the behavioral effect of escitalopram in chronically stressed male mice: involvement of NAPE-PLD expressed in parvalbumin-positive interneurons and the prefrontal cortexFranciele F Scarante, Vinícius D Lopes, Eduardo J Fusse, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|November 3, 2023
Cannabidiol as an Adjunctive Treatment for Acute Bipolar Depression: A Pilot Study: Le cannabidiol comme traitement d'appoint de la dépression bipolaire aiguë : une étude piloteJairo Vinícius Pinto, José Alexandre S Crippa, Keila Maria Ceresér, et al.
Scientific Reports|April 20, 2022
Potential cannabidiol (CBD) repurposing as antibacterial and promising therapy of CBD plus polymyxin B (PB) against PB-resistant gram-negative bacilliNathália Abichabki, Luísa V Zacharias, Natália C Moreira, et al.
Psychological Medicine|June 16, 2018
Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trialFernanda Palhano-Fontes, Dayanna Barreto, Heloisa Onias, et al.
JAMA Network Open|August 13, 2021
Efficacy and Safety of Cannabidiol Plus Standard Care vs Standard Care Alone for the Treatment of Emotional Exhaustion and Burnout Among Frontline Health Care Workers During the COVID-19 Pandemic: A Randomized Clinical TrialJosé Alexandre S Crippa, Antonio W Zuardi, Francisco S Guimarães, et al.
Frontiers in Pharmacology|October 20, 2022
Maintained anxiolytic effects of cannabidiol after treatment discontinuation in healthcare workers during the COVID-19 pandemicJosé Diogo S Souza, Antonio W Zuardi, Francisco S Guimarães, et al.
Cannabis and Cannabinoid Research|October 7, 2021
Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical TrialJosé Alexandre S Crippa, Julia Cozar Pacheco, Antonio W Zuardi, et al.
The American Journal of Psychiatry|December 7, 2016
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and TerminologyOliver D Howes, Rob McCutcheon, Ofer Agid, et al.
The American Journal of Psychiatry|October 8, 2025
Relapse in Schizophrenia: A Systematic Review of Criteria for Clinical Studies and International Consensus Guidelines to Improve ThemOliver D Howes, Bernard R Bukala, Eric Y H Chen, et al.
Pageof 13